OSE Immunotherapeutics Signs a License Option Agreement with Inserm to Develop a New Cancer Immunotherapy … – Business Wire (press release)
|
OSE Immunotherapeutics Signs a License Option Agreement with Inserm to Develop a New Cancer Immunotherapy …
Business Wire (press release) “We are very pleased to collaborate with an accomplished team whose foundational research in immunology complements our immunotherapy platform. This partnership strengthens our long-standing academic relationship and again demonstrates that … |
